Eris Lifesciences - Public Comps and Valuation Multiples

Eris Lifesciences Overview

About Eris Lifesciences

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.

Founded

2007

HQ

Employees

3.6K+

Website

eris.co.in

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $354M

LTM EBITDA $127M

EV

$2.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Eris Lifesciences Financials

As of November 2025, Eris Lifesciences reported last 12-month revenue of $354M and EBITDA of $127M.

In the same period, Eris Lifesciences generated $267M in LTM gross profit and $53.1M in net income.

See Eris Lifesciences valuation multiples based on analyst estimates

Eris Lifesciences P&L

In the most recent fiscal year, Eris Lifesciences reported revenue of $322M and EBITDA of $116M.

Eris Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Eris Lifesciences valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$354M	XXX	$322M	XXX	XXX	XXX
Gross Profit	$267M	XXX	$240M	XXX	XXX	XXX
Gross Margin	76%	XXX	75%	XXX	XXX	XXX
EBITDA	$127M	XXX	$116M	XXX	XXX	XXX
EBITDA Margin	36%	XXX	36%	XXX	XXX	XXX
EBIT	$93.0M	XXX	$78.7M	XXX	XXX	XXX
EBIT Margin	26%	XXX	24%	XXX	XXX	XXX
Net Profit	$53.1M	XXX	$39.4M	XXX	XXX	XXX
Net Margin	15%	XXX	12%	XXX	XXX	XXX
Net Debt	XXX	XXX	$249M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Eris Lifesciences including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $354M. EBITDA for the last twelve months was $127M. In the most recent fiscal year, Eris Lifesciences achieved $322M in revenue and $116M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$354M	Analyst estimates available to subscribers	$322M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$267M	Analyst estimates available to subscribers	$240M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	75.6% gross margin	Analyst estimates available to subscribers	74.6% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$127M	Analyst estimates available to subscribers	$116M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	35.9% EBITDA margin	Analyst estimates available to subscribers	36.0% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$93.0M	Analyst estimates available to subscribers	$78.7M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	26.3% EBIT margin	Analyst estimates available to subscribers	24.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$53.1M	Analyst estimates available to subscribers	$39.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	15.0% net profit margin	Analyst estimates available to subscribers	12.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$249M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Eris Lifesciences

This financial data table provides comprehensive performance metrics for Eris Lifesciences, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Eris Lifesciences generated $354M in revenue over the last twelve months.
The company achieved $127M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $267M.
Net income over the last twelve months reached $53.1M.

Fiscal Year Performance

In the most recent fiscal year, Eris Lifesciences reported $322M in total revenue.
Fiscal year EBITDA was $116M.
The company maintained a gross profit margin of 74.6% in the most recent fiscal year.
EBITDA margin for the fiscal year was 36.0%.
Net profit margin reached 12.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Eris Lifesciences. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Eris Lifesciences Stock Performance

Eris Lifesciences has current market cap of INR 215B (or $2.4B), and EV of INR 238B (or $2.7B).

Market Cap Evolution

Eris Lifesciences Stock Data

As of December 3, 2025, Eris Lifesciences's stock price is INR 1576 (or $18).

See Eris Lifesciences trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.7B	$2.4B	XXX	XXX	XXX	XXX	$0.43

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Eris Lifesciences Valuation Multiples

Eris Lifesciences's trades at 8.9x EV/Revenue multiple, and 25.0x EV/EBITDA.

See valuation multiples for Eris Lifesciences and 15K+ public comps

Eris Lifesciences Financial Valuation Multiples

As of December 3, 2025, Eris Lifesciences has market cap of $2.4B and EV of $2.7B.

Equity research analysts estimate Eris Lifesciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eris Lifesciences has a P/E ratio of 45.2x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.4B	XXX	$2.4B	XXX	XXX	XXX
EV (current)	$2.7B	XXX	$2.7B	XXX	XXX	XXX
EV/Revenue	7.5x	XXX	8.9x	XXX	XXX	XXX
EV/EBITDA	20.9x	XXX	25.0x	XXX	XXX	XXX
EV/EBIT	28.6x	XXX	36.5x	XXX	XXX	XXX
EV/Gross Profit	10.0x	XXX	n/a	XXX	XXX	XXX
P/E	45.2x	XXX	59.3x	XXX	XXX	XXX
EV/FCF	62.3x	XXX	30.8x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eris Lifesciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Eris Lifesciences Margins & Growth Rates

Eris Lifesciences's last 12 month revenue growth is 15%

Eris Lifesciences's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $45K for the same period.

Eris Lifesciences's rule of 40 is 51% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Eris Lifesciences's rule of X is 75% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Eris Lifesciences and other 15K+ public comps

Eris Lifesciences Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	15%	XXX	18%	XXX	XXX	XXX
EBITDA Margin	36%	XXX	36%	XXX	XXX	XXX
EBITDA Growth	19%	XXX	20%	XXX	XXX	XXX
Rule of 40	51%	XXX	51%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	75%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$45K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	9%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	0%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	50%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial